Key result
T2DM and IHD are linked to increased MPO activity versus healthy controls.
Why the study?
Is increased myeloperoxidase activity associated with ischemic heart disease risk in patients with diabetes mellitus?
Cross-Sectional
Is increased myeloperoxidase activity associated with ischemic heart disease risk in patients with diabetes mellitus?
Increased myeloperoxidase activity may serve as an additional diagnostic biomarker for predicting the risk of ischemic heart disease in patients with diabetes mellitus.
Using a previously developed spectrophotometric method (Bioorg. Khim. 2009, vol. 35, pp. 629–639) a significant increase of myeloperoxidase (MPO) activity (versus healthy control) was found in blood plasma of patients with type 2 diabetes mellitus (DM2) without cardiovascular complications, and also in patients with ischemic heart disease (IHD). The plasma MPO concentration measured by an enzyme-linked immunosorbent assay was significantly higher only in blood plasma of patients with DM2 and IHD. A significant positive correlation between blood MPO activity and blood MPO content was observed only in blood plasma samples from healthy donors. Increased MPO activity did not correlate with MPO concentration in blood plasma of patients with DM2 and DM2 with IHD. Taken together, these results indicate that studies on the MPO role in the development of pathological processes should include simultaneous determination of both the amount of enzyme and its peroxidase activity in blood of patients. The proposed approach gives comprehensive information about the relationship between MPO activity and MPO concentration in patient’s blood. Since the high concentration of MPO is a diagnostically important parameter for the prediction of development of endothelial dysfunction and cardiovascular diseases, the obtained results point to the contribution of MPO-dependent reactions in cardiovascular complications associated with diabetes mellitus. MPO activity may serve as an additional diagnostic criterion for determination of risk of IHD in DM patients.
No takes yet. Share an insight, caveat, or question.
Горудко et al. (2011) conducted a cross-sectional in Type 2 diabetes mellitus and ischemic heart disease. Myeloperoxidase (MPO) activity and concentration vs. Healthy controls was evaluated on Blood plasma MPO activity and concentration. Myeloperoxidase (MPO) activity was significantly increased in patients with type 2 diabetes mellitus and ischemic heart disease compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: